View More View Less
  • 1 Roche Molecular Diagnostics, Pleasanton, CA, USA
  • 2 Development, Roche Molecular Diagnostics, Pleasanton, CA, USA
  • 3 NorthShore University HealthSystem, Evanston, IL, USA

Clostridium difficile infection is a significant health burden, and innovative solutions are needed to shorten time to diagnosis and improve infection control. We evaluated the performance of the cobas® Cdiff test for use on the cobas® Liat® System (cobas® Liat® Cdiff), a single-sample, on-demand, and automated molecular solution with a 20-min turnaround time. The limit of detection was 45–90 colony-forming units (CFUs)/swab for toxigenic strains that covered the most prevalent toxinotypes, including the hypervirulent epidemic 027/BI/NAP1 strain. Using 442 prospectively collected clinical stool specimens, we compared the performance of the cobas® Liat® Cdiff to direct culture and to the cobas® Cdiff test on the cobas® 4800 System (cobas® 4800 Cdiff) – a mediumthroughput molecular platform. The sensitivity and specificity of the cobas® Liat® Cdiff compared to direct culture were 93.1% and 95.1%, respectively, and this performance did not statistically differ from the cobas® 4800 Cdiff (P > 0.05). Direct correlation of the cobas® Liat® and cobas® 4800 Cdiff tests yielded overall percent agreement of 98.6%. The test performance, automation, and turnaround time of the cobas® Liat® Cdiff enable its use for on-demand and out-of-hours testing as a complement to existing batch testing solutions like the cobas® 4800 Cdiff.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1.

    Leffler DA , Lamont JT: Clostridium difficile infection. N Engl J Med 372, 15391548 (2015)

  • 2.

    Martin JS , Monaghan TM, Wilcox MH: Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol 13, 206216 (2016)

    • Search Google Scholar
    • Export Citation
  • 3.

    Bassetti M , Villa G, Pecori D, Arzese A, Wilcox M: Epidemiology, diagnosis and treatment of Clostridium difficile infection. Expert Rev Anti Infect Ther 10, 14051423 (2012)

    • Search Google Scholar
    • Export Citation
  • 4.

    Bauer MP , Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ, Group ES: Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377, 6373 (2011)

    • Search Google Scholar
    • Export Citation
  • 5.

    Wiegand PN , Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S: Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 81, 114 (2012)

    • Search Google Scholar
    • Export Citation
  • 6.

    Zhang S , Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH: Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study. BMC Infect Dis 16, 447 (2016)

    • Search Google Scholar
    • Export Citation
  • 7.

    CDC: United States Centers for Disease Control and Prevention. Nearly half a million Americans suffered from Clostridium difficile infections in a single year. Page last reviewed March 22, 2017. Available at: https://www.cdc. gov/media/releases/2015/p0225-clostridium-difficile.html. [Last accessed: August 20, 2017]

    • Search Google Scholar
    • Export Citation
  • 8.

    Lessa FC , Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC: Burden of Clostridium difficile infection in the United States. N Engl J Med 372, 825834 (2015)

    • Search Google Scholar
    • Export Citation
  • 9.

    Cartman ST , Heap JT, Kuehne SA, Cockayne A, and Minton NP: The emergence of ‘hypervirulence’ in Clostridium difficile. Int J Med Microbiol 300, 387395 (2010)

    • Search Google Scholar
    • Export Citation
  • 10.

    Jones AM , Kuijper EJ, Wilcox MH: Clostridium difficile: a European perspective. J Infect 66, 115128 (2013)

  • 11.

    Fang FC , Polage CR, Wilcox MH: Point-counterpoint: what is the optimal approach for detection of Clostridium difficile infection? J Clin Microbiol 55, 670680 (2017)

    • Search Google Scholar
    • Export Citation
  • 12.

    Burnham CA , Carroll KC: Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev 26, 604630 (2013)

    • Search Google Scholar
    • Export Citation
  • 13.

    van Dorp SM , Notermans DW, Alblas J, Gastmeier P, Mentula S, Nagy E, Spigaglia P, Ivanova K, Fitzpatrick F, Barbut F, Morris T, Wilcox MH, Kinross P, Suetens C, Kuijper EJ, European Clostridium difficile Infection Surveillance Network project on behalf of all participants: Survey of diagnostic and typing capacity for Clostridium difficile infection in Europe, 2011 and 2014. Euro Surveill 21 (2016)

    • Search Google Scholar
    • Export Citation
  • 14.

    Polage CR , Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, Nguyen HH, Huang B, Tang YW, Lee LW, Kim K, Taylor S, Romano PS, Panacek EA, Goodell PB, Solnick JV, Cohen SH: Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 175, 17921801 (2015)

    • Search Google Scholar
    • Export Citation
  • 15.

    Butler MOA , Drekonja D, Shaukat A, Schwehr N, Shippee N, Wilt TJ: Early Diagnosis, Prevention, and Treatment of Clostridium difficile: Update. Comparative Effectiveness Review No. 172. (Prepared by the Minnesota Evidencebased Practice Center under Contract No. 290-2012-00016- I.) AHRQ Publication No. 16 EHC012-EF.Agency for Healthcare Research and Quality, Rockville, MD, March 2016.

    • Search Google Scholar
    • Export Citation
  • 16.

    Crobach MJ , Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, Wilcox MH, Kuijper EJ: European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 22 Suppl 4, S6381 (2016)

    • Search Google Scholar
    • Export Citation
  • 17.

    Bomers MK , Menke FP, Savage RS, Vandenbroucke-Grauls CM, van Agtmael MA, Covington JA, Smulders YM: Rapid, accurate, and on-site detection of C. difficile in stool samples. Am J Gastroenterol 110, 588594 (2015)

    • Search Google Scholar
    • Export Citation
  • 18.

    Kundrapu S , Jury LA, Sitzlar B, Sunkesula VC, Sethi AK, Donskey CJ: Easily modified factors contribute to delays in diagnosis of Clostridium difficile infection: a cohort study and intervention. J Clin Microbiol 51, 23652370 (2013)

    • Search Google Scholar
    • Export Citation
  • 19.

    Scheurer D : Diagnostic and treatment delays in recurrent Clostridium difficile-associated disease. J Hosp Med 3, 156159 (2008)

  • 20.

    FDA: United States Food and Drug Administration – Nucleic Acid Based Tests: List of Microbial Tests. This is a list of nucleic acid-based tests that have been cleared or approved by the Center for Devices and Radiological Health. These tests analyze variations in the sequence, structure, or expression of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in order to diagnose disease or medical conditions, infection with an identifiable pathogen, and determine genetic carrier status.

    • Search Google Scholar
    • Export Citation
  • 21.

    Peterson LR , Young SA, Davis TE Jr, Wang ZX, Duncan J, Noutsios C, Liesenfeld O, Osiecki JC, Lewinski MA: Evaluation of the cobas(R) Cdiff test for the detection of toxigenic Clostridium difficile in stool samples. J Clin Microbiol 2017.

    • Search Google Scholar
    • Export Citation
  • 22.

    Buchan BW , Ledeboer NA: Emerging technologies for the clinical microbiology laboratory. Clin Microbiol Rev 27, 783822 (2014)

  • 23.

    Robinson A , Marcon M, Mortensen JE, McCarter YS, LaRocco M, Peterson LR, Thomson RB Jr: Controversies affecting the future practice of clinical microbiology. J Clin Microbiol 37, 883889 (1999)

    • Search Google Scholar
    • Export Citation
  • 24.

    Halligan E , Edgeworth J, Bisnauthsing K, Bible J, Cliff P, Aarons E, Klein J, Patel A, Goldenberg S: Multiplex molecular testing for management of infectious gastroenteritis in a hospital setting: a comparative diagnostic and clinical utility study. Clin Microbiol Infect 20, O460467 (2014)

    • Search Google Scholar
    • Export Citation
  • 25.

    Melchers WJG , Kuijpers J, Sickler JJ, Rahamat-Langendoen J: Lab-in-a-tube: real-time molecular point-of-care diagnostics for influenza A and B using the cobas(R) Liat(R) system. J Med Virol 89, 13821386 (2017)

    • Search Google Scholar
    • Export Citation
  • 26.

    cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System. Manufacturers Instructions for Use. For In Vitro Diagnostic Use. Roche Molecular Systems, Inc., Marlborough, MA, USA (2017).

    • Search Google Scholar
    • Export Citation
  • 27.

    Moure R , Canizares A, Muino M, Lobato M, Fernandez A, Rodriguez M, Gude MJ, Tomas M, Bou G: Use of the cobas 4800 system for the rapid detection of toxigenic Clostridium difficile and methicillin-resistant Staphylococcus aureus. J Microbiol Methods 120, 5052 (2016)

    • Search Google Scholar
    • Export Citation
  • 28.

    Kociolek LK , Gerding DN: Clinical utility of laboratory detection of Clostridium difficile strain BI/NAP1/027. J Clin Microbiol 54, 1924 (2016)

    • Search Google Scholar
    • Export Citation
  • 29.

    Rupnik M : Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol Rev 32, 541555 (2008)

    • Search Google Scholar
    • Export Citation
  • 30.

    O’Connor JR , Johnson S, Gerding DN: Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136, 19131924 (2009)

    • Search Google Scholar
    • Export Citation
  • 31.

    Gerding DN , Johnson S, Rupnik M, Aktories K: Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes 5, 1527 (2014)

    • Search Google Scholar
    • Export Citation
  • 32.

    Eckert C , Emirian A, Le Monnier A, Cathala L, De Montclos H, Goret J, Berger P, Petit A, De Chevigny A, Jean-Pierre H, Nebbad B, Camiade S, Meckenstock R, Lalande V, Marchandin H, Barbut F: Prevalence and pathogenicity of binary toxin-positive Clostridium difficile strains that do not produce toxins A and B. New Microbes New Infect 3, 1217 (2015)

    • Search Google Scholar
    • Export Citation
  • 33.

    Eyre DW , Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L, Ip, CLC, Golubchik T, Batty EM, Finney JM, Wyllie DH, Didelot X, Piazza P, Bowden R, Dingle KE, Harding RM, Crook DW, Wilcox MH, Peto TEA, Walker AS: Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 369, 11951205 (2013)

    • Search Google Scholar
    • Export Citation
  • 34.

    Senchyna F , Gaur RL, Gombar S, Truong CY, Schroeder LF, Banaei N: Clostridium difficile PCR cycle threshold predicts free toxin. J Clin Microbiol 2017.

    • Search Google Scholar
    • Export Citation
  • 35.

    Longtin Y , Gilca R, Loo VG: Effect of detecting and isolating asymptomatic Clostridium difficile carriers-reply. JAMA Intern Med 176, 1573 (2016)

    • Search Google Scholar
    • Export Citation
  • 36.

    Tenover FC , Baron EJ, Peterson LR, Persing DH: Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty? J Mol Diagn 13, 573582 (2011)

    • Search Google Scholar
    • Export Citation
  • 37.

    Goldenberg SD , Bisnauthsing KN, Patel A, Postulka A, Wyncoll D, Schiff R, French GL: Point-of-care testing for Clostridium difficile infection: a real-world feasibility study of a rapid molecular test in two hospital settings. Infect Dis Ther 3, 295306 (2014)

    • Search Google Scholar
    • Export Citation
  • 38.

    Hui-Hsing W : Assessing Strategies to Improve the Market for Rapid Diagnostics for Bacterial Diseases Session III: Addressing the post-market economic challenges to diagnostics development (Presentation). April 18, 2017. Washington, DC.

    • Search Google Scholar
    • Export Citation
  • 39.

    Cohen-Bacrie S , Ninove L, Nougairede A, Charrel R, Richet H, Minodier P, Badiaga S, Noel G, La Scola B, de Lamballerie X, Drancourt M, Raoult D: Revolutionizing clinical microbiology laboratory organization in hospitals with in situ point-of-care. PLoS One 6, e22403 (2011)

    • Search Google Scholar
    • Export Citation
  • 40.

    Patel PA , Schora DM, Singh K, Liesenfeld O, Peterson LR: Validation of active surveillance testing for Clostridium difficile colonization using the cobas® Cdiff test (in submission).

    • Search Google Scholar
    • Export Citation
  • 41.

    Mason J : Point-of-care testing for influenza. CADTH Issues in Emerging Health Technologies. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON), 2016 Nov, 149.

  • 42.

    Moore C : Point-of-care tests for infection control: should rapid testing be in the laboratory or at the front line? J Hosp Infect 85, 17 (2013)

    • Search Google Scholar
    • Export Citation

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2020 0 4 5
Dec 2020 0 2 4
Jan 2021 0 4 3
Feb 2021 0 4 7
Mar 2021 0 8 11
Apr 2021 0 1 0
May 2021 0 0 0